Lincoln Pharmaceuticals Ltd. announces 32nd AGM on Sep 30, 2026, proposes ₹1.80 dividend
Lincoln Pharmaceuticals Limited will hold its 32nd AGM on September 30, 2026, via VC/OAVM. The company proposes a dividend of ₹1.80 per share for FY26 and will consider re-appointing two directors. Financial statements for FY26 will also be adopted.
The AGM announcement and dividend proposal are material events for shareholders. The re-appointment of directors and adoption of financial statements are standard procedures.
The announcement is a routine corporate event (AGM notice) with standard proposals like dividend declaration and director re-appointments. It does not contain significant positive or negative financial news.
Lincoln Pharmaceuticals Limited has announced its 32nd Annual General Meeting (AGM) will be held on Wednesday, September 30, 2026, at 11:00 a.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting will consider and adopt the audited standalone and consolidated financial statements for the financial year ended March 31, 2026.
Additionally, the company proposes to declare a dividend of ₹1.80 per equity share (18%) on shares of ₹10 each for the financial year 2025-2026. Two Whole Time Directors, Mr. Hashmukh I. Patel and Mr. Munjal Mahendrabhai Patel, who are retiring by rotation, will be considered for re-appointment.
The AGM will also seek to ratify the remuneration of ₹2,50,000 per annum plus applicable taxes and out-of-pocket expenses to Kiran J. Mehta & Co. as cost auditors for the financial year ending March 31, 2027. The notice of the AGM and the Annual Report for 2025-2026 have been sent to members electronically.
What to do with a filing like this
Lincoln Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Lincoln Pharmaceuticals Limited. Read the original for the full detail.